Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, Dockendorf MF, Egan M, Ereshefsky L, Hodgson RA, Hyde LA, Jhee S, Kleijn HJ, Kuvelkar R, Li W, Mattson BA, Mei H, Palcza J, Scott JD, Tanen M, Troyer MD, Tseng JL, Stone JA, Parker EM, Forman MS. Kennedy ME, et al. Among authors: stone ja. Sci Transl Med. 2016 Nov 2;8(363):363ra150. doi: 10.1126/scitranslmed.aad9704. Sci Transl Med. 2016. PMID: 27807285
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.
Iwamoto M, Kassahun K, Troyer MD, Hanley WD, Lu P, Rhoton A, Petry AS, Ghosh K, Mangin E, DeNoia EP, Wenning LA, Stone JA, Gottesdiener KM, Wagner JA. Iwamoto M, et al. Among authors: stone ja. J Clin Pharmacol. 2008 Feb;48(2):209-14. doi: 10.1177/0091270007310382. Epub 2007 Dec 12. J Clin Pharmacol. 2008. PMID: 18077730 Clinical Trial.
A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design.
Peng JZ, Denney WS, Musser BJ, Liu R, Tsai K, Fang L, Reitman ML, Troyer MD, Engel SS, Xu L, Stoch A, Stone JA, Kowalski KG. Peng JZ, et al. Among authors: stone ja. AAPS J. 2014 Nov;16(6):1259-70. doi: 10.1208/s12248-014-9648-x. Epub 2014 Aug 27. AAPS J. 2014. PMID: 25160589 Free PMC article. Clinical Trial.
Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.
Chris Min K, Dockendorf MF, Palcza J, Tseng J, Ma L, Stone JA, Kleijn HJ, Hodsman P, Masuo K, Tanen M, Troyer MD, van Vugt M, Forman MS. Chris Min K, et al. Among authors: stone ja. Clin Pharmacol Ther. 2019 May;105(5):1234-1243. doi: 10.1002/cpt.1258. Epub 2019 Jan 18. Clin Pharmacol Ther. 2019. PMID: 30347431 Clinical Trial.
Safety, Tolerability, and Pharmacokinetics of the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects.
Forman M, Palcza J, Tseng J, Stone JA, Walker B, Swearingen D, Troyer MD, Dockendorf MF. Forman M, et al. Among authors: stone ja. Clin Transl Sci. 2019 Sep;12(5):545-555. doi: 10.1111/cts.12645. Epub 2019 Jun 19. Clin Transl Sci. 2019. PMID: 31215755 Free PMC article. Clinical Trial.
332 results